BridgeBio has significantly advanced its development of the novel therapy for cardiac amyloidosis, leveraging the compound. Preliminary patient data suggests promising improvements for patients suffering with this https://attrcm630858.articlesblogger.com/64544281/company-progresses-cardiac-amyloidosis-treatment-with-the-drug